CDMO

Recent developments

Capacity build‑outs

CDMOs expanded capacity. WuXi Biologics advanced assets with the topping‑out of its modular Drug Product facility at the Singapore CRDMO Hub, the first GMP run at MFG17 at the Shanghai Fengxian site, and structural completion of the Chengdu microbial manufacturing site. AGC Biologics readied the Yokohama Site and added U.S. drug‑product via a strategic partnership with Pyramid Pharma Services. Evonik will upgrade Tippecanoe Labs and expand drug‑substance capacity in Slovakia.

Regulatory milestones

Clearances supported commercial supply. WuXi Biologics reported FDA PLI clearance for the MFG8 drug substance facility, ANVISA GMP for MFG2, DP1 and DPPC, and South Korea MFDS GMP certification; its Suzhou Biosafety Testing Center earned a fourth EMA GMP certificate. AGC Biologics’ Seattle facility obtained ANVISA GMP.

Modality advances

RNA and complex‑biologics platforms progressed. Wacker Biotech and Eclipsebio partnered on end‑to‑end RNA design and GMP production, and WACKER launched Contract Research Services for nucleic‑acid medicines. Asahi Kasei deployed an FO–MD system at Peptistar and licensed precision ADC technology for controlled DAR and site‑specific conjugation.

Strategy and portfolio

Evonik continued realignment by selling selected pharmaceutical‑ingredient assets in Hanau to the ProChem Group and opening an Open Pharma Lab in Yokohama. WACKER’s Q2 2026 results reflected cost savings and a pension effect. Mitsubishi Gas Chemical and Veritas In Silico filed a nucleic acid drug targeting lncRNA H19. CELLforCURE sought a buyer amid a weaker CGT project pipeline.

Regional initiatives

Public financing targeted medical‑isotope and vaccine supply: the EIB backed Orano Med’s Advanced Thorium Extraction Facility, and partners supported Biovac to build Africa’s first end‑to‑end vaccine manufacturing facility. ESG performance remained in focus, with WuXi Biologics included in the S&P Global Sustainability Yearbook (China Edition).